Literature DB >> 27300430

Pancreatic Cancer: Planning Ahead for Metastatic Spread.

Ingunn M Stromnes1, Philip D Greenberg2.   

Abstract

Metastasis and therapy resistance are cardinal features of pancreatic ductal adenocarcinoma, a commonly lethal malignancy. In this issue of Cancer Cell, Steele et al. show that CXCR2 expression and neutrophils are required for metastasis. In mice treated with advanced disease, inhibiting both CXCR2 and PD1 cooperatively but not individually prolongs survival.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27300430     DOI: 10.1016/j.ccell.2016.05.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  5 in total

1.  CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2.

Authors:  Lingdong Meng; Yihan Zhang; Pengfei Wu; Danrui Li; Yichao Lu; Peng Shen; Taoyue Yang; Guodong Shi; Qun Chen; Hao Yuan; Wanli Ge; Yi Miao; Min Tu; Kuirong Jiang
Journal:  Mol Cancer       Date:  2022-06-01       Impact factor: 41.444

2.  Human pancreatic cancer progression: an anarchy among CCN-siblings.

Authors:  Sushanta K Banerjee; Gargi Maity; Inamul Haque; Arnab Ghosh; Sandipto Sarkar; Vijayalaxmi Gupta; Donald R Campbell; Daniel Von Hoff; Snigdha Banerjee
Journal:  J Cell Commun Signal       Date:  2016-08-19       Impact factor: 5.782

Review 3.  Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.

Authors:  Helen Ha; Bikash Debnath; Nouri Neamati
Journal:  Theranostics       Date:  2017-04-07       Impact factor: 11.556

4.  Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferative effects by DMAPT in pancreatic cancer cells.

Authors:  Chen Shi; Yang Wang; Yuna Guo; Yijun Chen; Nan Liu
Journal:  Oncotarget       Date:  2017-05-23

5.  Bicyclo[2.2.1]heptane containing N,N'-diarylsquaramide CXCR2 selective antagonists as anti-cancer metastasis agents.

Authors:  Jin-Xin Che; Zhi-Long Wang; Xiao-Wu Dong; You-Hong Hu; Xin Xie; Yong-Zhou Hu
Journal:  RSC Adv       Date:  2018-03-21       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.